• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Applied DNA Sciences Inc.

    7/24/25 6:29:50 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email
    S-8 1 tm2521623d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on July 24, 2025

     

    Registration No. 333-  

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Applied DNA Sciences, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction

    of incorporation or organization)

    59-2262718

    (I.R.S. Employer Identification No.)

     

     

    50 Health Sciences Drive

    Stony Brook, New York

    (Address of Principal Executive Offices)

    11790

    (Zip Code)

     

     

    Applied DNA Sciences, Inc. 2020 Equity Incentive Plan

    (Full title of the plan)  

     

    Judith Murrah

    Chief Executive Officer

    Applied DNA Sciences, Inc.

    50 Health Sciences Drive

    Stony Brook, New York 11790

    Telephone: (631) 240-8800 

    (Name and address of agent for service)

     

    Copies to:

     

    Merrill M. Kraines, Esq.

    Todd Kornfeld, Esq.

    McDermott Will & Emery LLP

    One Vanderbilt Avenue

    New York, New York 10017-3852

    Telephone: (212) 547-5616

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨ Accelerated filer   ¨
    Non-accelerated filer   x Smaller reporting company   x
          Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement relates to the registration of an additional 200,000 shares of common stock, $0.001 par value per share (the “Common Stock”), for future issuance pursuant to awards under the 2020 Equity Incentive Plan (the “2020 Plan”) of Applied DNA Sciences, Inc. (the “Company”). Such additional shares being registered are of the same class as other securities of the Company for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective. In accordance with General Instruction E to Form S-8, the contents of the Company’s previous Registration Statements on Form S-8 related to the 2020 Plan (Commission File Nos. 333-249365 and 333-282414), filed on October 7, 2020 and September 30, 2024, respectively, with the U.S. Securities and Exchange Commission (the “Commission”), are incorporated herein by reference and made part of this Registration Statement, except as amended or otherwise modified or superseded hereby. Effective as of May 22, 2025, the date of the approval by the Company’s stockholders of the amendment of the 2020 Plan, the total number of shares of Common Stock that may be issued under the 2020 Plan has been increased to 200,500 shares of Common Stock from 500 shares of Common Stock. The total number of shares of Common Stock issuable under the 2020 Plan gives effect to the reverse stock split of the Company’s outstanding common stock at a ratio of one-for-fifteen shares, which became effective as of 12:01 a.m. Eastern Time on June 2, 2025.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Commission.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. Incorporation of Documents by Reference.

     

    The Commission allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the Commission will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents and information previously filed with the Commission:

     

    (i) Our Annual Report on Form 10-K for the fiscal year September 30, 2024 filed with the Commission on December 17, 2024;
       
    (ii) Our Quarterly Reports on Form 10-Q for the periods ended December 31, 2024, filed with the Commission on February 13, 2025, and March 31, 2025, filed with the Commission on May 15, 2025, respectively;
       
    (iii) Our Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed with the Commission on October 31, 2024, November 7, 2024, November 13, 2024, December 17, 2024, January 23, 2025, January 30, 2025, February 14, 2025, February 28, 2025, March 12, 2025, April 1, 2025, April 8, 2025, May 22, 2025, May 29, 2025, June 6, 2025, June 17, 2025, June 30, 2025 and July 7, 2025; and
       
    (iv) The description of our Common Stock contained in our registration statement on Form 8-A (File No. 001-36745) filed on November 13, 2014, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

     

    In addition to the foregoing, all documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than, in each case, documents or information, including, without limitation, any applicable exhibits, deemed to have been “furnished” and not “filed” in accordance with the rules and regulations issued by the Commission), subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

      

    Exhibit
    No.
      Exhibit
    Description
    3.1*+   Conformed version of Certificate of Incorporation of Applied DNA Sciences, Inc., as most recently amended by the Eighth Certificate of Amendment, effective June 2, 2025
         
    3.2   Conformed version of By-Laws, as amended by the Certificate of Amendment to the By-Laws, effective November 7, 2024 (incorporated by reference to Exhibit 3.2 of the registrant’s Registration Statement on Form S-1 filed on November 19, 2024)
         
    5.1*   Opinion of McDermott Will & Emery LLP
         
    10.1   Conformed version of Applied DNA Sciences, Inc. 2020 Equity Incentive Plan, as most recently amended by the Amendment to the Applied DNA Sciences, Inc. 2020 Equity Incentive Plan, effective May 22, 2025 (incorporated by reference to Appendix C of the registrant’s Definitive Proxy Statement, filed with the Commission on April 15, 2025)
         
    10.2   Applied DNA Sciences, Inc. 2020 Equity Incentive Plan Stock Option Grant Notice and Award Agreement (incorporated by reference to Exhibit 10.3 of the registrant’s Form S-8 filed on October 7, 2020)
         
    23.1*   Consent of McDermott Will & Emery LLP (contained in Exhibit 5.1)
         
    23.2*   Consent of Marcum LLP, independent registered public accounting firm
         
    24.1*   Power of Attorney (included as part of signature page to this Registration Statement)
         
    107*   Filing Fee Table

     

     

    * Filed herewith.

    + This exhibit is being filed pursuant to Item 601(b)(3)(i) of Regulation S-K which requires a conformed version of the Company’s charter reflecting all amendments in one document. The exhibit reflects the Company’s Certificate of Incorporation, as previously amended, as most recently amended by the Eighth Certificate of Amendment, effective June 2, 2025.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Stony Brook, State of New York, on July 24, 2025.

     

    APPLIED DNA SCIENCES, INC.  
       
    By: /s/ Judith Murrah  
      Judith Murrah  
      Chief Executive Officer, President, Chairperson & Director  

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below appoints Ms. Judith Murrah and Ms. Beth Jantzen, and each of them, any of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and any registration statement (including any amendment thereto) for this offering that is to be effective upon filing pursuant to Rule 462 under the Securities Act and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or would do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them of their or his or her substitute and substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Judith Murrah   Chief Executive Officer, President, Chairperson & Director   July 24, 2025
    Judith Murrah   (Principal Executive Officer),    
             
    /s/ Beth Jantzen   Chief Financial Officer   July 24, 2025
    Beth Jantzen   (Principal Financial and Accounting Officer)    
             
    /s/ Robert B. Catell   Director   July 24, 2025
    Robert B. Catell        
             
    /s/ Joseph D. Ceccoli   Director   July 24, 2025
    Joseph D. Ceccoli        
             
    /s/ Sanford R. Simon   Director   July 24, 2025
    Sanford R. Simon        
             
    /s/ Yacov A. Shamash   Director   July 24, 2025
    Yacov A. Shamash        
             
    /s/ Elizabeth Schmalz Shaheen   Director   July 24, 2025
    Elizabeth Schmalz Shaheen        

     

     

     

    Get the next $APDN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    SEC Filings

    See more
    • SEC Form S-8 filed by Applied DNA Sciences Inc.

      S-8 - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      7/24/25 6:29:50 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Other Events

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      7/7/25 4:05:36 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      6/30/25 4:05:52 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

      2/11/22 6:29:21 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

      8/13/21 6:30:16 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

      4/22/21 6:37:35 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Jantzen Beth

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:56 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Shorrock Clay

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:40 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Murrah Judith

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:30 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

      - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

      1/10/25 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

      STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.About Applied DNA Sciences

      1/8/25 4:30:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

      - Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synt

      12/18/24 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

      Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

      9/6/23 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

      STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

      4/1/21 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Financials

    Live finance-specific insights

    See more
    • Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

      STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

      12/16/24 10:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

      STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

      8/7/24 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

      STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting period. The Company will host an investor update call on June 12, 2024.Summary Second Quarter Fiscal 2024 Financial Results:Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter

      5/10/24 4:05:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Applied DNA Sciences Inc.

      SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/14/24 5:46:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/13/24 4:15:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/7/24 10:11:34 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary